About
About Bioheng
History
Science & Products
Pipelines
Technology Platforms
Publications
Patients
Expanded access
News
Event Highlights
Contact
Investor Relations&BD
23
2025-12
Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
11
Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting
Imviva Biotech Presents Clinical Breakthroughs for CTD402 in High-Mortality T-Cell and Myeloid Leukemias at the 67th American Society of Hematology Annual Meeting
25
2025-11
Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting
30
2025-10
Imviva Biotech Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CTD402 in Relapsed/Refractory T-ALL/LBL
Contact Us
Consult Now
